Rare access focus KnippeRx specializes in rare, orphan, and ultra-orphan therapies, presenting a clear sales opportunity to manufacturers and payers seeking specialized distribution, streamlined access, and patient-centric support for high-need drug programs.

End-to-end support As an affiliate of J. Knipper and Company with expertise in samples and logistics, KnippeRx can position as a partner for integrated supply chain solutions, patient assistance programs, and temperature-controlled biologics handling.

High-touch services The emphasis on personalized patient assistance, PAP, starter dispensing, and temperature-controlled therapies suggests collaboration opportunities with manufacturers and providers to improve initiation rates and adherence in challenging therapeutic areas.

Tech-enabled engagement Utilize KnippeRx's tech stack including AWS, Google Cloud, Power BI, MuleSoft and analytics to offer data-driven targeting, forecasting, and performance dashboards for sales teams and strategic accounts, enhancing program outcomes.

Growth readiness With estimated revenue in a low-to-mid multi-million range and a lean team (51-200 employees), there is potential to scale partnerships with larger distributors or PBMs by showcasing nimble operations and specialized capabilities in handling high-complexity therapies.